BioSpace News Archive

Curis, Inc. announced that on January 3, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 224,700 shares of Curis common stock to eleven new employees, with a grant date of January 3, 2022.

Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 94,000 shares of Dynavax common stock and restricted stock units covering an aggregate of 2,500 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company.

Atara Biotherapeutics, Inc. reported the grant of an aggregate of 57,164 restricted stock units of Atara’s common stock to 12 newly hired employees and stock options to purchase an aggregate of 64,925 shares of Atara’s common stock to seven such newly hired employees.

Natus Medical Incorporated announced that Thomas J. Sullivan, President and Chief Executive Officer, and Drew Davies, Executive Vice President and Chief Financial Officer, will be presenting at the 24th Annual Needham Virtual Growth Conference from 2:00 PM to 2:40 PM ET on Friday, January 14th.

Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to nine new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Stealth BioTherapeutics Corp announced that on January 4, 2022, it received a letter from The Nasdaq Stock Market LLC, notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5450.

Merck, known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2021 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Thursday, Feb. 3. During the call, company executives will provide an overview of Merck’s performance for the quarter and outlook.

Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 7,000 shares of the Company’s common stock with an exercise price of $2.45 per share, the closing price of Assembly Bio’s common stock on January 3, 2022.

Sorrento Therapeutics, Inc. announced the unexpected passing of Mr. Najjam Asghar, Chief Financial Officer and Senior Vice President.

TCR2 Therapeutics Inc. announced that Garry Menzel, President and Chief Executive Officer of TCR2 Therapeutics, will present an update on Company progress at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30AM E.T. using a virtual platform.